Prevalence of human immunodeficiency virus RNA and antibody in first‐time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios
- 17 October 2013
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 53 (10pt2), 2399-2412
- https://doi.org/10.1111/trf.12299
Abstract
Twenty-one blood organizations from five geographical regions provided HIV individual donation (ID)-NAT and serology data on 11,787,610 donations. Infections were classified as anti-HIV-/RNA+ window period (WP), anti-HIV+/RNA+ concordant positive (CP) or anti-HIV+/RNA- elite controller (EC). Residual risk and efficacy of several screening scenarios were estimated for first time, lapsed and repeat donations. WP residual risk estimates assumed a 50% infectious dose of 3.16 virions and a 50% detection limit of 2.7 HIV RNA copies/mL for ID-NAT and 10,000 copies/mL for p24Ag. Infectivity for CP (100%) and EC (2.2%) donations was estimated based on viral load distributions and 100-fold reduced infectivity by antibody neutralization as reported elsewhere. Efficacy was calculated as proportion of transmission risk removed from baseline (i.e. in absence of any screening). There was no significant difference in transmission risk between lapsed and repeat donations in any region. Risk was 3.8-fold higher in first time than combined lapsed/repeat donations in South Africa but not in other regions. Screening strategies were most efficacious at interdicting infectious transfusions in first time (98.7-99.8%) followed by lapsed (97.6-99.7%) and repeat (86.8-97.7%) donations in all regions combined. In each donor category the efficacy of ID-NAT alone (97.7-99.8%) was superior to that of minipool (MP)-NAT/anti-HIV (95.0-99.6%) and p24 Ag/anti-HIV (89.8-99.1%). Efficacy patterns were similar by donor/donation status in each region despite large differences in HIV prevalence and transmission risk. As similar data become available for HBV and HCV, this modeling may be useful in cost effectiveness analyses of alternative testing scenarios.Keywords
This publication has 24 references indexed in Scilit:
- Comparison of human immunodeficiency virus assays in window phase and elite controller samples: viral load distribution and implications for transmission riskTransfusion, 2013
- International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009Vox Sanguinis, 2011
- Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithmsTransfusion, 2010
- Infectivity of human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusionTransfusion, 2009
- Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South AfricaTransfusion, 2009
- High Specific Infectivity of Plasma Virus from the Pre-Ramp-Up and Ramp-Up Stages of Acute Simian Immunodeficiency Virus InfectionJournal of Virology, 2009
- Human Immunodeficiency Virus Controllers: Mechanisms of Durable Virus Control in the Absence of Antiretroviral TherapyImmunity, 2007
- Dynamics of HIV viremia and antibody seroconversion in plasma donorsAIDS, 2003
- Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window‐phase donations not detected by NATTransfusion, 2002
- Factors Influencing Human Immunodeficiency Virus Type 1 Transmission by Blood TransfusionThe Journal of Infectious Diseases, 1996